Recent studies have shown that percutaneous coronary intervention (PCI) activates systemic hemostatic activity, reflecting platelet activation and thrombin formation in the coronary arteries. The present study compared systemic levels of hemostatic markers induced by plain old balloon angioplasty (POBA), coronary stenting (STENT), and cutting balloon (CB) angioplasty.
PERCUTANEOUS coronary intervention (PCI) has become an indispensable part of the therapeutic strategy for coronary heart disease. To overcome the limitations of plain old balloon angioplasty (POBA) for coronary artery lesions, eg, acute coronary occlusion, coronary dissection and restenosis, new devices have been developed, such as coronary stenting, directional coronary atherectomy, rotational atherectomy, and cutting balloon angioplasty. The cutting balloon (CB) is designed as a novel balloon catheter equipped with 3 or 4 metal blades mounted on the surface of the balloon. 1, 2) Angioplasty with CB produces sharp and regular endovascular incisions that cause less histological damage than POBA. Recent studies have shown that markers of hemostatic activity rise systemically following PCI, reflecting platelet activation and thrombin formation in the coronary arteries. 3) This procoagulant condition at the site of the intervention might contribute to unfavorable outcomes, eg, subacute thrombus formation or restenosis. The present study compared systemic levels of hemostatic markers induced by POBA, coronary stenting, and CB angioplasty to determine the magnitude of hemostasis activation produced by each intervention.
METHODS
Patients: Sixty-one patients with stable angina pectoris who had no myocardial infarction (40 men and 21 women, mean age 61 ± 13 years) underwent elective PCI or diagnostic coronary angiography (CAG) alone were enrolled. Patients who underwent PCI were divided into three groups, a POBA group (n = 11), a STENT group (n = 27) consisting of patients who underwent coronary stenting, and a CB group (n = 11) consisting of patients who underwent CB angioplasty. Patients who underwent CAG alone were assigned to the CAG group (n = 12). All patients in the POBA, STENT, and CB groups had > 75% stenosis of a coronary artery (or arteries) by visual inspection and met clinical criteria for PCI. Patients with acute coronary syndrome were excluded from this study. Informed consent was obtained from all patients before blood sampling. Medication: Aspirin (162 mg/day) was administered orally to all patients in the POBA, STENT, and CB groups. In the CAG group, 9 patients received aspirin. Ticlopidine (200 mg/day) was administered to 5 patients in the POBA group, 22 in the STENT group, 5 in the CB group, and 4 in the CAG group. Cilostazol (200 mg/day) was given to 3, 5, 6, and 3 patients in the POBA, STENT, CB, and CAG groups, respectively. No patient received warfarin. Pravastatin (5-20 mg/day) was administered to 5 patients in the POBA group, 12 in the STENT group, 5 in the CB group, and 5 in the CAG group. All patients in the POBA, STENT, and CB groups received 100 U/kg of intravenous heparin sodium as a bolus injection Vol 45 No 3 immediately before PCI. After PCI, patients in the POBA and CB groups received a continuous infusion of heparin (10,000 U/24 hours). Coronary angiography and angioplasty: CAG was performed using nonionic contrast media. Angioplasty and stenting were performed in a routine manner with an appropriately sized balloon using an 8 French guiding catheter. Before CAG, we inserted a sheath into a femoral artery: 8.2 French for PCI and 6 French for diagnostic CAG. In the CAG group, the sheaths were removed soon after CAG was completed. In the POBA, STENT, and CB groups, the sheaths were removed 3 hours after PCI.
Angiographic results were analyzed by experienced angiographers blinded to the angioplasty procedure. Using a QCA system (CCIP-310, Cathex, Tokyo, Japan), the percent diameter stenosis and minimal lumen diameter were measured before and after PCI using matched views. Angiographic measurements were made during diastole using the guiding catheter as a reference. Blood samples and measurements: Blood samples were collected before, 24 hours after, and 3 days after PCI or CAG. Prior to PCI or diagnostic CAG, blood samples were collected through the femoral arterial sheath. Twenty-four hours after and 3 days after PCI or CAG, peripheral blood samples were obtained from a superficial antecubital vein using a 21-gauge needle. Blood samples were withdrawn slowly in all cases to minimize hemostatic activation. When blood samples were obtained through the femoral arterial sheath, the first 2 mL of blood was discarded and the sample was collected in syringes containing 3.8% sodium citrate or EDTA. The samples were immediately put on ice and centrifuged at 3000 rpm for 15 minutes at 4°C to obtain platelet-poor plasma, then frozen at -80°C until the assays were performed. Plasma concentrations of heparin, prothrombin fragment 1+2 (F1+2), fibrinopeptide A (FPA), thrombin-antithrombin III complex (TAT), and plasminogen activator inhibitor-1 (PAI-1) were measured. F1+2, FPA, and TAT are markers of the generation and activation of thrombin, and PAI-1 is a marker of fibrinolytic activation. Statistical analysis: Statistical analysis was performed using Stat-View 4.02 on a Macintosh Centris 650 computer. Student's paired t test was used to evaluate serial changes in variables. Categorical variables were compared by Fisher's exact test. A level of P < 0.05 was considered statistically significant.
RESULTS

Demographics and clinical characteristics of study patients:
The demographic and clinical characteristics of the study patients are summarized in Table I . Implanted stents included the Palmaz-Schatz stent (n = 14), NIR stent (n = 6), Gianturco-Roubin stent (n = 5), and ACT-One stent (n = 2) (all single stentings).
Age, gender distribution, severity of angina pectoris, and coronary risk factors were similar in the POBA, STENT, CB, and CAG groups. The ratio of patients receiving aspirin, ticlopidine, cilostazol, or pravastatin was similar in the four groups. Angiographic characteristics of study patients: The angiographic characteristics of the study patients in each group are shown in Table II . The maximum inflation pressure in the CB group was lower than in the POBA and STENT groups. However, other parameters and results related to the intervention were similar.
Patients in the POBA, STENT, and CB groups received heparin. Although continuous intravenous heparin infusion (10,000 U/24 hours) was begun following the bolus injection in the POBA and CB groups, heparin levels were undetectable 24 hours after PCI in all groups (data not shown). Sequential changes in thrombin markers: Table III shows the sequential changes in the serum concentration of the thrombin markers (F1+2, FPA, and TAT). In the CB and CAG groups, the F1+2, FPA, and TAT concentrations before, 24 hours after, and 3 days after PCI or CAG were similar. In the POBA and STENT groups, the F1+2, FPA, and TAT concentrations continued to rise during the 3 days of the study. The F1+2 concentration in the POBA group was highest and it was higher than that in the STENT, CB, and CAG groups 3 days after PCI or CAG (P < 0.05). The FPA concentrations in the POBA and STENT groups were higher 3 days after PCI than in the CB and CAG groups (P < 0.05). The TAT concentration in the POBA group continued to rise throughout the study, but the con- centration in the STENT group peaked 24 hours after PCI and subsequently decreased. The TAT concentration in the POBA and STENT groups was higher 3 days after PCI than in the CB and CAG groups (P < 0.05). Sequential changes in fibrinolytic markers: Table IV shows the sequential changes in the serum concentration of the fibrinolytic marker, PAI-1. The PAI-1 concentration in the CB and CAG groups did not change during the 3 days after PCI or CAG. The PAI-1 concentration in the POBA and STENT groups was elevated at 24 hours, but had decreased by 3 days. Three days after PCI, the PAI-1 concentrations in the POBA and STENT groups were higher than in the CB group (P < 0.05).
DISCUSSION
The major finding of this study is that systemic concentrations of F1+2, FPA, TAT, and PAI-1 increase significantly after POBA and stenting but do not rise after CB angioplasty.
Changes in hemostatic activation markers following PCI have been studied by several investigators. Oltrona, et al 4) and Schammas, et al 3) followed these markers for a short interval after PCI and found no change. However, heparin injection before PCI might have suppressed activation. 5) Thrombus formation in the coronary arteries is regulated by several factors including, 1) thrombin formation followed by hemostatic activation, 2) fibrinolytic activation, and 3) platelet activation. For this reason, we selected markers of thrombin formation and fibrinolytic activation as indices of hemostatic activation after PCI.
Thrombin is a very unstable and easily degraded substance that cannot be measured directly. F1+2, FPA, and TAT are thought to be markers which reflect thrombin formation. It is unknown which is the most reliable marker of thrombin generation after PCI. The serum F1+2 concentration exceeds the normal only in severe hypercoagulable states, 4, 6) and Haude, et al 7) showed that the F1+2 concentration is the most specific and useful predictor of subacute stent thrombosis. FPA is very sensitive and indicates coagulation activity in real time because of its short half-life time. The FPA level is not thought to be affected by heparin administration, but it can be affected by a number of artifacts during blood drawing and performing the assay. 4) The TAT level is known to be affected by heparin. Our previous investigation showed that F1+2 is the most stable marker of thrombin formation after PCI. We found no differences in serum F1+2, FPA, TAT, and PAI-1 concentrations in blood drawn from femoral arteries and peripheral veins in a previous study (data not shown). Therefore, we felt justified comparing data using blood drawn from femoral arteries with data from blood drawn from peripheral veins. Although blood sampling from the coronary sinus may be more sensitive for monitoring hemostatic activation in the coronary arteries, it has been reported that concentrations of some hemostatic markers are similar in blood drawn from the coronary sinus and a peripheral vein. 4) Differences in hemostatic and fibrinolytic activation following PCI have yet to be studied in detail. This is the first study to compare the immediate (24 hours) and short-term (3 days) effects of PCI on these hematologic processes.
We found that hemostatic and fibrinolytic activation is less following CB angioplasty than after POBA or stenting, and the degree of thrombin generation and fibrinolytic activation was similar to that following CAG. This fact may be related to the differences between the dilation mechanism of CB angioplasty and other devices. CB angioplasty produces microsurgical incisions that result in smoother vessel dilatation, prevent elastic recoil, and generate less intimal proliferation. 1) Based on current experience, CB angioplasty is especially appropriate for lesions in which the outcome after POBA often is poor, eg, small vessel disease, 8) long diffuse lesions, bifurcation lesions, ostial lesions including aortoostial lesions, 9) and in-stent restenosis. 10) Experimental studies and many clinical studies have recently shown that HMG-CoA reductase inhibitors (statins) produce favorable effects on hemostatic parameters, including those that are risk factors for cardiovascular disease. 11) Statins diminish procoagulant activity, which is observed at different stages of the coagulation cascade, including tissue factor activity, conversion of prothrombin to thrombin, and thrombin activity. 11) In some studies, statins also reduced fibrinogen levels. By altering the levels and activities of tissue-type plasminogen activator and PAI-1, statins seem to stimulate fibrinolysis. 11) In this study, pravastatin administration might have affected hemostatic and fibrinolytic markers in each group. However, the rates of patients who received pravastatin in each group showed no significant difference. Therefore, we think that pravastatin administration had no effect on the differences in hemostatic and fibrinolytic markers in each group.
A variety of mechanisms have been proposed to account for restenosis after PCI. Thrombin and other substances released from activated platelets act as growth factors for vascular smooth muscle cells, resulting in intimal proliferation that is the main cause of in-stent restenosis. If dilatation-induced vascular injury is reduced, then platelet activation and thrombin generation also will be less, reducing the amount of restenosis, especially of in-stent restenosis. Therefore, we believe that CB angioplasty is a better choice than POBA when the risk of restenosis is high because the magnitude of vascular injury is lower, as reflected by lower serum concentrations of hemostatic activation markers.
The mechanism of CB angioplasty has been explained as follows. The plaque is first cut by the blades and then the artery is dilated by the balloon. 12) The three or four radially directed blades create longitudinal vascular incisions before the balloon inflation is completed, so balloon pressure primarily extends these incisions. While some vascular injury is unavoidable, the damage is better controlled and localized to the area of incisions, sparing the interincisional segments. Thus, growth factor expression, DNA synthesis, and cell proliferation are localized to the incisions rather than occurring circumferentially in the area of the dilation. Inoue, et al 13) have shown lower expression of neutrophil adhesion molecule after CB than POBA, and suggested that this difference reflects less vessel wall injury and might explain the lower rate of restenosis with the CB device. Study limitations: A limitation of this study is that we used some kinds of stents for patients which might influence the results of hemostatic markers in the STENT group. We have no data about the differences in hemostatic and fibrinolytic markers among stents. We could not prescribe the entirely same drugs in each group, and we also have no data about the differences in hemostatic markers among medications. In this study, we were unable to investigate the relationship between systemic hemostatic and fibrinolytic activation and restenosis after PCI, which needs further investigation. Conclusions: Based on the serum concentrations of hemostatic markers as indices of vascular injury, CB angioplasty causes less vascular damage than POBA, which in turn may translate into a superior long-term outcome by decreasing the rate of restenosis.
